Sanofi (SAN.PA)

Paris - Paris Delayed Price. Currency in EUR

Add to watchlist

85.11+1.16 (+1.38%)

At close: 5:39PM CEST

Advertisement

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	83.95
Open	83.98
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	83.84 - 85.45
52 Week Range	74.92 - 91.14
Volume	1,655,448
Avg. Volume	1,643,413

Market Cap	106.832B
Beta (5Y Monthly)	0.41
PE Ratio (TTM)	18.47
EPS (TTM)	4.61
Earnings Date	Oct 28, 2021
Forward Dividend & Yield	3.20 (3.76%)
Ex-Dividend Date	May 05, 2021
1y Target Est	101.58

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SAN.PA

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Yahoo Finance Video
Pfizer says vaccine is 90.7% effective in kids aged 5 to 11: BBG
Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- FDA says benefits outweigh risks for Pfizer/BioNTech COVID-19 vaccine in children
  Reuters
- Pfizer's vaccine is over 90 percent effective against symptomatic COVID-19 in kids
  The Week
Insider Monkey
10 High-Yield Dividend Stocks to Buy According to Ken Fisher
In this article, we discuss the 10 high-yield dividend stocks to buy according to Ken Fisher. If you want to skip our detailed analysis of these stocks, go directly to the 5 High-Yield Dividend Stocks to Buy According to Ken Fisher. Ken Fisher is the chief of Fisher Asset Management, a Washington-based hedge fund with […]
GlobeNewswire
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease Pivotal trial met primary and all key secondary endpointsDupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeksData reinforce impact of targeting IL-4 and IL-13, key and central drivers of type 2 infl